<DOC>
	<DOCNO>NCT02093533</DOCNO>
	<brief_summary>Membranoproliferative glomerulonephritis ( MPGN ) third fourth lead cause end stage renal disease among primary glomerulonephritis . Hyperactivation alternative complement pathway familial form type MPGN report suggest genetic abnormality may play predispose role disease . In recent case report Eculizumab , monoclonal antibody bind C5 prevent formation membrane attack complex , safe effective therapy .</brief_summary>
	<brief_title>Eculizumab Primary MPGN</brief_title>
	<detailed_description />
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis , Membranoproliferative</mesh_term>
	<criteria>Biopsyproven primary MPGN Creatinine clearance &gt; 20 ml/min per 1.73m2 24hour proteinuria persistently exceed 3,5g adult exceed 40mg/h/m2 child ( exceed 2mg protein/mg creatinine child spot urine sample ) Persistently low C3 level least two consecutive evaluation Persistently high sC5b9 level ( &gt; 1000 ng/ml ) least two previous consecutive evaluation Written inform consent ( parent tutor underage ) Age â‰¥75 year Secondary MPGN ( evidence infection , immunological disease include vasculitis , systemic disease proliferative disorder ) Evidence kidney biopsy evaluation severe chronic histological change unlikely could benefit eculizumab therapy Concomitant steroid immunosuppressive therapy immunomediated disease Pregnancy lactate Childbearing potential without effective contraception Any clinically relevant condition might affect completion study participation and/or confound study result Inability understand potential risk benefit study Legal incapacity</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Membranoproliferative glomerulonephritis</keyword>
	<keyword>Nephrotic syndrome</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Alternative complement pathway</keyword>
	<keyword>Complement inhibition</keyword>
	<keyword>Eculizumab</keyword>
</DOC>